Skip to main content
SpringerLink
Log in

Current and emerging treatments based on novel mechanisms for immune thrombocytopenia

  • Insight
  • Published:
Science China Life Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Al-Samkari, H., and Kuter, D.J. (2018). An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia. Br J Clin Pharmacol 84, 2673–2677.

    Article  CAS  Google Scholar 

  • Boccia, R., Boxer, M.A., Ghanima, W., Hill, Q.A., Sholzberg, M., Tarantino, M.D., Kreychman, Y., Numerof, R.P., Olender, B., Todd, L., et al. (2019). Enhanced responses to fostamatinib as second-line therapy and in persistent immune thrombocytopenia (ITP) patients. Blood 134, 1069.

    Article  Google Scholar 

  • Bussel, J.B., Saleh, M.N., Vasey, S.Y., Mayer, B., Arning, M., and Stone, N. L. (2013). Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP). Br J Haematol 160, 538–546.

    Article  CAS  Google Scholar 

  • Bussel, J., Arnold, D.M., Grossbard, E., Mayer, J., Trelihski, J., Homenda, W., Hellmann, A., Windyga, J., Sivcheva, L., Khalafallah, A.A., et al. (2018). Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol 93, 921–930.

    Article  CAS  Google Scholar 

  • Dai, L., Zhang, R., Wang, Z., He, Y., Bai, X., Zhu, M., Yu, Z., and Ruan, C. G. (2016). Efficacy of immunomodulatory therapy with all-trans retinoid acid in adult patients with chronic immune thrombocytopenia. Thromb Res 140, 73–80.

    Article  CAS  Google Scholar 

  • Feng, F.E., Feng, R., Wang, M., Zhang, J.M., Jiang, H., Jiang, Q., Lu, J., Liu, H., Peng, J., Hou, M., et al. (2017). Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial. Lancet Haematol 4, e487–e496.

    Article  Google Scholar 

  • Fu, H., Zhao, J., Xu, L., Liu, K., Wang, Y., Chen, H., Han, W., Wang, J., Wang, F., Huang, X., et al. (2019). Reduced β2-GPI is associated with increased platelet aggregation and activation in patients with prolonged isolated thrombocytopenia after allo-HSCT. Sci China Life Sci 62, 921–929.

    Article  CAS  Google Scholar 

  • He, Y., Xu, L.L., Feng, F.E., Wang, Q.M., Zhu, X.L., Wang, C.C., Zhang, J. M., Fu, H.X., Xu, L.P., Liu, K.Y., et al. (2018). Mesenchymal stem cell deficiency influences megakaryocytopoiesis through the TNFAIP3/NF-κB/SMAD pathway in patients with immune thrombocytopenia. Br J Haematol 180, 395–411.

    Article  CAS  Google Scholar 

  • Huang, Q.S., Xue, J., Wang, C.C., Qin, Y.Z., Xu, L.P., Liu, K., Huang, X.J., and Zhang, X.H. (2019). ATRA could correct the defective S1P-mediated cytoskeletal reorganization in proplatelet formation of ITP. Blood 134, 218.

    Article  Google Scholar 

  • Kiessling, P., Lledo-Garcia, R., Watanabe, S., Langdon, G., Tran, D., Bari, M., Christodoulou, L., Jones, E., Price, G., Smith, B., et al. (2017). The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study. Sci Transl Med 9, eaan1208.

    Article  Google Scholar 

  • Newland, A.C., Sánchez-González, B., Rejtő L., Egyed, M., Romanyuk, N., Godar, M., Verschueren, K., Gandini, D., Ulrichts, P., Beauchamp, J., et al. (2020). Phase 2 study ofefgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am J Hematol 95, 178–187.

    Article  CAS  Google Scholar 

  • Robak, T., Kaźmierczak, M., Jarque, I., Musteata, V., Trelinski, J., Cooper, N., Kiessling, P., Massow, U., Woltering, F., Snipes, R., et al. (2019). Rozanolixizumab, an anti-FcRn antibody: final results from a phase II, multiple-dose study in patients with primary immune thrombocytopenia. Blood 134, 897.

    Article  Google Scholar 

  • Visani, G., Ottaviani, E., Zauli, G., Tosi, P., Pellacani, A., Isidori, A., Pierpaoli, S., and Tura, S. (1999). All-trans retinoic acid at low concentration directly stimulates normal adult megakaryocytopoiesis in the presence of thrombopoietin or combined cytokines. Eur J Haematol 63, 149–153.

    Article  CAS  Google Scholar 

  • Xu, L.L., Fu, H.X., Zhang, J.M., Feng, F.E., Wang, Q.M., Zhu, X.L., Xue, J., Wang, C.C., Chen, Q., Liu, X., et al. (2017). Impaired function of bone marrow mesenchymal stem cells from immune thrombocytopenia patients in inducing regulatory dendritic cell differentiation through the Notch-1/Jagged-1 signaling pathway. Stem Cells Dev 26, 1648–1661.

    Article  CAS  Google Scholar 

  • Xue, J., Feng, R., Fu, H., Jiang, Q., Jiang, H., Lu, J., Liu, H., Wang, J., Niu, T., Wang, X., et al. (2018). Combined prednisone and levothyroxine improve treatment of severe thrombocytopenia in hepatitis B with compensatory cirrhosis accompanied by subclinical and overt hypothyroidism. Sci China Life Sci 61, 924–933.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by Beijing Municipal Science and Technology Commission (Z171100001017084), Key Program of National Natural Science Foundation of China (81730004), and Beijing Natural Science Foundation (7171013).

Author information

Authors and Affiliations

  1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, 100044, China

    Qiaozhu Zeng & Xiaohui Zhang

  2. Collaborative Innovation Center of Hematology, Peking University, Beijing, 100044, China

    Qiaozhu Zeng & Xiaohui Zhang

  3. Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China

    Qiaozhu Zeng & Xiaohui Zhang

  4. National Clinical Research Center for Hematologic Disease, Beijing, 100044, China

    Qiaozhu Zeng & Xiaohui Zhang

Authors
  1. Qiaozhu Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaohui Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiaohui Zhang.

Additional information

Compliance and ethics

The author(s) declare that they have no conflict of interest.

Supporting Information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zeng, Q., Zhang, X. Current and emerging treatments based on novel mechanisms for immune thrombocytopenia. Sci. China Life Sci. 63, 1597–1599 (2020). https://doi.org/10.1007/s11427-020-1757-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11427-020-1757-2

Search

Navigation